PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 323 (xsd:integer)
nif:isString
  • Importantly, in TCGA, all patients with BRCA2 mutated tumors receiving cisplatin-based chemotherapy (n = 6 out of 62 patients) responded (vs. 34/56 for BRCA2 wt, p = 0.08; Fisher’s exact test; Fig. 2i), while 6/7 patients with ERCC2 mutated tumors responded (vs. 34/55 for ERCC2 wt, p = 0.40; Fisher’s exact test; Fig. 2j).
rdf:type